<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) remains incurable despite advances in new strategies of treatment, including monoclonal antibodies (MoAb) </plain></SENT>
<SENT sid="1" pm="."><plain>Except for early stages, FL is characterized by responses to treatments and systematic relapses </plain></SENT>
<SENT sid="2" pm="."><plain>The main objective in this disease is to achieve a better progression free survival (PFS) and to increase overall survival (OS), mainly in young patients </plain></SENT>
<SENT sid="3" pm="."><plain>In order to improve the results of conventional chemotherapy, autologous stem cell transplant (ASCT) is a feasible treatment in these patients </plain></SENT>
<SENT sid="4" pm="."><plain>In this moment, ASCT is not recommended as first line treatment, except for transformed FL, but is a good strategy as salvage therapy with an improved PFS and OS </plain></SENT>
<SENT sid="5" pm="."><plain>New drugs have been introduced to enhance responses of ASCT, but nowadays they are not part of conventional conditioning regimen </plain></SENT>
</text></document>